Denis Drygin - 12 Jan 2022 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Chief Scientific Officer
Signature
Christopher Aker, Attorney in Fact
Issuer symbol
RGLS
Transactions as of
12 Jan 2022
Net transactions value
$0
Form type
4
Filing time
26 Jan 2022, 15:14:33 UTC
Next filing
07 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +400,000 $0.000000 400,000 12 Jan 2022 Common Stock 400,000 $0.2600 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.